8,911 findings · published 2022+
- Energy balanceStrong
Further studies with larger samples and long-term follow-up are needed.
Encourage ongoing research to validate and refine strength training protocols for this population.
Qualifies 2025New - Metabolic adaptationStrong
No significant differences in metabolic flexibility were observed between the RE+CON and RE+PRO groups.
Combining resistance exercise with either a control or high protein diet does not significantly alter metabolic flexibility outcomes.
Refutes 2026New - CellularStrong
Adipositas ist eine multifaktorielle Erkrankung mit global steigender Prävalenz.
Practitioners should recognize the multifactorial nature of obesity when addressing it in patients.
Supports 2025New - Energy balanceStrong
Das Programm ist aufgrund tiefer Gruppentarife der Krankenversicherer in der Schweiz für Anbieter nicht kostendeckend.
Anbieter sollten die wirtschaftlichen Aspekte des Programms berücksichtigen.
Refutes 2022 - Energy balanceStrong
Total protein and animal protein were not associated with all-cause, CVD, or cancer mortality.
Practitioners should note that total and animal protein intake does not impact mortality risk.
Refutes 2025New - Energy balanceStrong
ASFs can play an important role in circular and diverse agroecosystems that can help restore biodiversity and mitigate greenhouse gas emissions.
Sustainable farming practices for ASFs should be promoted to enhance environmental benefits.
Supports 2023 - MolecularStrong
Human evidence for causality between the gut microbiome and body weight remains scarce.
Recognize the need for more research on the gut microbiome's role in obesity.
Supports 2023 - MolecularStrong
The decision tree yields an area under the receiver operating characteristic curve (AUC) of 0.967 for PCOS diagnosis.
Clinicians can use this decision tree to improve the accuracy of PCOS diagnosis.
Supports 2022 - Energy balanceStrong
The current evidence does not demonstrate Blautia’s direct involvement as a pathogenic microbe in obesity development or progression.
Practitioners should consider that Blautia may not be a direct target for obesity treatment based on current evidence.
Refutes 2024 - Energy balanceStrong
Access to new antiobesity medications is severely limited despite their potential to combat obesity.
Practitioners should be aware of the barriers to access for new antiobesity medications.
Supports 2022 - NeuralStrong
Increasing levels of neurofilament light chain (NfL) are associated with worsening cognitive function and incident mild cognitive impairment or probable dementia.
Monitoring NfL levels may help in assessing cognitive decline in patients with T2D and obesity.
Supports 2025New - NeuralStrong
Increasing levels of glial fibrillary acidic protein (GFAP) are associated with worsening cognitive function and incident mild cognitive impairment or probable dementia.
Tracking GFAP levels may provide insights into cognitive health in patients with T2D and obesity.
Supports 2025New - Energy balanceStrong
Increasing baseline blood-based biomarker levels were not associated with any cognitive composite z score.
Baseline BBM levels may not be useful for predicting cognitive function in this population.
Refutes 2025New - CellularStrong
Wash-in and washout effects can threaten the validity of short-term dietary trials.
Researchers should consider the timing of interventions and outcomes in dietary trials to ensure validity.
Supports 2025New - Energy balanceStrong
Approximately two-thirds of patients who achieved remission relapsed within 1 year.
Practitioners should prepare for potential relapse in patients post-remission.
Supports 2023 - CellularStrong
Type 2 Diabetes Mellitus (T2DM) is characterized by tissue insulin resistance and loss of pancreatic β cell function.
Understanding the nature of T2DM is crucial for effective management strategies.
Supports 2023 - MolecularStrong
Innovative drug delivery systems are being developed to improve the efficacy of oral antidiabetic medications.
Practitioners should consider new drug delivery methods to enhance treatment outcomes for T2DM.
Supports 2023 - CellularStrong
The term 'prediabetes' does not adequately describe the cellular changes occurring in individuals with dysglycemia.
Awareness of the limitations of the term 'prediabetes' can improve clinical understanding.
Supports 2024 - MolecularStrong
The encapsulated oleogel-in-oleogel system has tailorable lipid digestion compared to conventional oleogels.
This system could be used to create food products with lower calorie content and customizable fat digestion profiles.
Supports 2024 - MolecularStrong
The encapsulated oleogel-in-oleogel system maintains the nanostructure of waxes and monoglyceride crystals.
Maintaining the nanostructure could enhance the functional properties of food products using this system.
Supports 2024 - MolecularStrong
The digestibility of the encapsulated oleogel-in-oleogel system can be modulated by varying the ratio of its components.
This flexibility allows for the design of food products tailored to specific dietary needs.
Supports 2024 - MolecularStrong
GIPR activation influences energy balance and insulin sensitivity through mechanisms involving metabolic and thermogenic genes.
Understanding the molecular mechanisms of GIPR could inform strategies for improving insulin sensitivity.
Supports 2023 - Energy balanceStrong
Nutrition is relevant along the criminal justice continuum.
Nutrition should be integrated into discussions and interventions within the criminal justice system.
Supports 2024 - NeuralStrong
Innovative therapeutics focused on hunger control are being considered for patients with rare genetic obesities.
Clinicians may consider new pharmacological options for managing hunger in patients with rare genetic obesities.
Supports 2023